Clinical outcome of SARS-CoV-2 infection in 7 adults with Duchenne muscular dystrophy attending a specialist neuromuscular centre
Authors:
- 26 April 2021
- journal article
- research article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 31 (7) , 603-606
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- COVID-19 in children with neuromuscular disordersJournal of Neurology, 2021
- The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysisClinical Cardiology, 2020
- Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemicJournal of Neurology, 2020
- COVID-19 and neuromuscular disordersNeurology, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespanThe Lancet Neurology, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic managementThe Lancet Neurology, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementThe Lancet Neurology, 2018